$10.50
▲ +1.7% Today
as of Jul 22, 16:55 ET
Last 30 days
Recent Press Releases & News
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Reports First Patient Dosing in Phase 3 Kidney Cancer Trial
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
Overview
52-week range
$6.28
$18
35% of range
Avg surprise (last 0)
—
Avg reaction (last 0)
—
Earnings trends
Implied volatility — last 90 days
No IV snapshots yet for TLX.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.